HYPERION THERAPEUTICS INC

HYPERION THERAPEUTICS INC insiders are currently net buyers of HPTX stock, showing neutral sentiment over the past 90 days. Executives have purchased $67.2M while selling $33.8M, resulting in a positive net flow of $33.4M. This buying activity represents 67% of total transaction volume.

HYPERION THERAPEUTICS INC has 40 active insiders who have filed SEC Form 4 transactions in the past 90 days. Ryan D. Drant (Executive) leads with 20 transactions totaling $114.7M. Peter J. Barris (Executive) follows with 20 transactions worth $114.7M. Open-market purchases require insiders to invest their own capital, demonstrating genuine conviction.

The Insider Alignment Score measures the ratio of buying to selling activity on a 0-100 scale. HYPERION THERAPEUTICS INC's current score of 67/100 indicates neutral insider sentiment. Scores above 60 suggest insiders are accumulating shares faster than selling, reflecting $67.2M in purchases versus $33.8M in sales.

The most recent insider transaction occurred on May 7, 2015, when G. Welch Daniel (Executive) disposed of 2,617 shares at $46.00 per share for $120.4K. This appears to be a discretionary trade.

Based on SEC Form 4 filings from the past 90 days, HPTX insider trading sentiment is currently neutral with an Alignment Score of 67/100. The net insider flow of $33.4M reflects accumulation, with 67% of volume being purchases.

SEC Form 4 is the primary disclosure mechanism for insider trading at publicly traded companies like HYPERION THERAPEUTICS INC. Corporate insiders must file within two business days of any transaction, making it one of the most timely sources of executive sentiment. At HPTX, we track all Form 4 filings—currently showing 462 transactions from 40 insiders over 90 days.

A 10b5-1 plan allows HYPERION THERAPEUTICS INC executives to pre-schedule stock sales when they don't possess material non-public information. At HPTX, approximately 0% of recent transactions are 10b5-1 trades. Most trading activity at HPTX appears discretionary, making insider signals more meaningful.

You can monitor HYPERION THERAPEUTICS INC (HPTX) insider trading activity on this page, which updates within hours of new SEC Form 4 filings. We track all 40 active insiders and provide real-time transaction feeds, the Alignment Score, 10b5-1 vs. discretionary breakdowns, and direct links to SEC EDGAR filings.

Our Alignment Score measures the ratio of insider buying to selling on a scale of 0-100. A score above 70 indicates strong bullish sentiment, while below 30 suggests bearish activity. HYPERION THERAPEUTICS INC's current score of 67/100 indicates moderately bullish sentiment suggesting insider confidence. This is calculated from $67.2M in purchases versus $33.8M in sales over 90 days, resulting in a net flow of $33.4M.

SEC Form 4 filings are mandatory reports that HYPERION THERAPEUTICS INC insiders must submit within 2 business days. Each filing includes the insider's name, relationship, transaction type, shares, and price. Transaction codes: P (purchase), S (sale), A (award), M (option exercise), G (gift). At HPTX, the most common type is "U" with 26 occurrences. The most recent Form 4 was filed on May 7, 2015 by G. Welch Daniel.

Rule 10b5-1 allows corporate insiders to establish pre-scheduled trading plans when they don't possess material non-public information. At HYPERION THERAPEUTICS INC, approximately 0% of recent transactions are executed under 10b5-1 plans, while 100% appear to be discretionary trades. The low percentage means most insider activity at HPTX represents discretionary decisions with more informational value.